The Efficacy and Safety of Endoscopic Sleeve Gastroplasty as an Alternative to Laparoscopic Sleeve Gastrectomy
| Autor: | Román Turró Arau, Jin Young Yoon |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
safety
medicine.medical_specialty obesity lcsh:Internal medicine efficacy Medicine (miscellaneous) 03 medical and health sciences 0302 clinical medicine FOCUSED REVIEW SERIES: Endoscopic Managements for Patients with Obesity and Its Related Comorbidities Weight loss medicine Radiology Nuclear Medicine and imaging lcsh:RC799-869 Adverse effect lcsh:RC31-1245 laparoscopic sleeve gastroplasty Laparoscopic sleeve gastrectomy Gastric emptying business.industry Gastroenterology Reflux medicine.disease Obesity Surgery Blood pressure 030220 oncology & carcinogenesis 030211 gastroenterology & hepatology lcsh:Diseases of the digestive system. Gastroenterology endoscopic sleeve gastroplasty Steatosis medicine.symptom business |
| Zdroj: | Clinical Endoscopy, Vol 54, Iss 1, Pp 17-24 (2021) Clinical Endoscopy |
| ISSN: | 2234-2443 2234-2400 |
| Popis: | Endoscopic sleeve gastroplasty (ESG) is a therapeutic endoscopic technique for reducing the size of the gastric reservoir in obese patients, using a full-thickness endoscopic suturing device. The effectiveness of ESG in weight loss is significantly greater than that of high-intensity diet and lifestyle therapy and lower than that of laparoscopic sleeve gastrectomy (LSG). The efficacy at 12 months after ESG in terms of percentage of total body weight loss and excess body weight loss was approximately 16% and 60%, respectively. The well-known predictive factors for increased weight loss by ESG are good compliance with regular monitoring and post-procedure care involving a multidisciplinary team approach. Although the underlying mechanism of weight loss induced by ESG is debatable, delayed gastric emptying and early satiation are some of the proposed mechanisms. The pooled rate of adverse events after ESG reported in several meta-analysis studies ranged from 1.5% to 2.3% and the incidence of new-onset gastroesophageal reflux disease after ESG was negligible, indicating that ESG has a superior safety profile to LSG. Moreover, ESG reduced the risk of obesity-related metabolic comorbidities, evidenced by the reduction in HbA1c level, systolic blood pressure, triglyceride level, and risk of hepatic steatosis and fibrosis; it even improved the quality of life. ESG could be considered safe and qualify as an alternative treatment to LSG. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|